Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:44:49 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



News for U:ALNY from 2023-05-18 to 2024-05-17 - 38 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-07 08:00U:ALNYNews ReleaseAlnylam Issues 2023 Corporate Responsibility Report
2024-05-02 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-04-30 07:00U:ALNYNews ReleaseMedison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
2024-04-30 07:00U:ALNYNews ReleaseMedison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
2024-04-18 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
2024-04-07 08:00U:ALNYNews ReleaseAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
2024-03-20 08:00U:ALNYNews ReleaseAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
2024-03-13 07:30U:ALNYNews ReleaseAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
2024-03-05 07:30U:ALNYNews ReleaseAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
2024-02-27 08:30U:ALNYNews ReleaseAlnylam to Webcast Presentations at Upcoming March Investor Conferences
2024-02-15 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
2024-01-29 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
2024-01-09 08:05U:ALNYNews ReleaseAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen ¢ € ™s Association
2024-01-07 18:00U:ALNYNews ReleaseAlnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
2024-01-02 07:30U:ALNYNews ReleaseAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 07:30U:ALNYNews ReleaseAlnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
2023-12-06 08:00U:ALNYNews ReleaseAlnylam to Webcast Virtual R&D Day
2023-11-30 08:00U:ALNYNews ReleaseAlnylam Ranks #1 on Boston Globe ¢ € ™s Top Places to Work List for 2023
2023-11-11 16:00U:ALNYNews ReleaseAlnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
2023-11-07 08:00U:ALNYNews ReleaseAlnylam to Webcast Presentations at Upcoming November Investor Conferences
2023-11-02 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-10-26 14:00U:ALNYNews ReleaseAlnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
2023-10-25 17:19U:ALNYNews ReleaseAlnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
2023-10-25 11:05U:ALNYNews ReleaseAlnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer ¢ € ™s Disease and Cerebral Amyloid Angiopathy
2023-10-19 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
2023-10-09 07:30U:ALNYNews ReleaseAlnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-10-06 07:00U:ALNYNews ReleaseAlnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
2023-09-13 16:57U:ALNYNews ReleaseAlnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-09-13 07:00U:ALNYNews ReleaseAlnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-09-07 07:00U:ALNYNews ReleaseAlnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
2023-08-25 17:00U:ALNYNews ReleaseAlnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
2023-08-03 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
2023-08-02 08:30U:ALNYNews ReleaseAlnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
2023-07-24 01:00U:ALNYNews ReleaseAlnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
2023-07-20 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
2023-07-17 02:21U:ALNYNews ReleaseAlnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer ¢ € ™s Disease and Cerebral Amyloid Angiopathy
2023-06-30 09:00U:ALNYNews ReleaseAlnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO ‚ ® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
2023-06-05 16:00U:ALNYNews ReleaseAlnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference